MOTS-c
Also known as: Mitochondrial ORF of the 12S rRNA type-c
Buy in shop
MOTS-c
5 verified vendors, side by side on real prices.
Key Facts: MOTS-c
- Category
- Hormonal
- FDA Status
- Not FDA Approved
- Clinical Status
- Preclinical/Early Clinical - FDA removed MOTS-c from Category 2 effective April 22, 2026. PCAC voted 7-5 to recommend MOTS-c for the 503A authorized compounding bulks list on July 23, 2026. The first Western Phase 2a RCT (NCT07505745, 120 participants with prediabetes, 16 weeks, primary endpoint: insulin sensitivity) is actively recruiting as of 2026. Non-binding advisory recommendation; formal FDA rulemaking required before legal compounding. No FDA approval for any indication. Effective October 30, 2026, HHS published Federal Register Document 2026-22192, an interim enforcement discretion policy that conditionally permits 503A compounding pharmacies to compound MOTS-c while formal rulemaking proceeds. Conditions include pharmaceutical-grade API sourcing, certificates of analysis, patient-specific prescriptions only, and single-API formulations only. This does not add MOTS-c to the FDA 503A Bulks Drug Substances List and is not a final rule. Rulemaking is pending with no timeline stated.
- Banned in Sport (WADA)
- Prohibited at all times under WADA S4 (metabolic modulators, AMPK activators), where MOTS-c is named.
- Administration
- Subcutaneous injection
- Typical Dose
- 5-10 mg weekly
- Frequency
- 1-3x weekly
- Duration
- Variable by protocol
How does MOTS-c work?
MOTS-c works largely through the AMPK pathway, the cell's main energy and fuel-gauge system. The proposed route is that MOTS-c interferes with the folate-AICAR-one-carbon metabolism cycle, which raises AICAR and activates AMPK in skeletal muscle, liver, and fat. Once AMPK is switched on, cells burn more fatty acids, take up more glucose, and ramp up mitochondrial biogenesis. MOTS-c can also move into the cell nucleus under metabolic stress and influence stress-response genes, which is unusual for a mitochondrial peptide and is part of why it is framed as a stress-adaptive signal. Treat the exact pathway details as a working model rather than settled fact, since much of it is still being mapped.
What does the research show?
In mice, MOTS-c is genuinely impressive: it improves insulin sensitivity, protects against diet-induced obesity, and older animals given MOTS-c run longer on a treadmill, which is where the exercise-mimetic label comes from. The human story is much thinner. The strongest human finding is observational: exercise raises MOTS-c, with reports of roughly a 12-fold jump in skeletal muscle and about a 1.6-fold rise in circulation after exercise, suggesting it may be one natural messenger behind some exercise benefits. But that is correlation, not proof that injecting MOTS-c reproduces those benefits. As of 2026 there are no completed, published randomized human trials showing that supplemental MOTS-c causes weight loss, better metabolic health, or longer life in people. It is also a known anti-doping target, which tells you it is treated as experimental and performance-relevant, not as an established therapy.
What doses have been studied?
Note: Animal study doses may not translate directly to humans.
Typical Dosingⓘ
Community experience
5-10 mg weekly
5-15 mg per week
1-3x weekly
A mitochondrial peptide studied in metabolic research. Reported protocols time it to exercise days, most often two to three times weekly.
Research Dosingⓘ
Scientific studies
Doses from research protocols
Doses from Studies
Research doses varied significantly
Duration
Variable by protocol
Administration
Subcutaneous injection
When and how is MOTS-c taken?
Best Time to Take
Morning or pre-workout
3-5 times per week
Food Recommendation
Take on empty stomach
Why This Timing?
MOTS-c enhances metabolic function and exercise capacity. Morning/pre-exercise timing optimizes benefits.
What are the side effects of MOTS-c?
Not everyone experiences these effects. Individual responses vary based on dosage, duration, and personal factors.
- ●Generally well-tolerated
- ●Injection site reactions (persistent bumps)
- ●Palpitations
- ●Nausea and bloating
- ●Fatigue
- ●May trigger histamine release - use caution with MCAS or histamine sensitivity
- ●Potential interactions with metformin
- ●Long-term effects unknown
References
- https://pmc.ncbi.nlm.nih.gov/articles/PMC9905433/
- https://pmc.ncbi.nlm.nih.gov/articles/PMC9854231/
- https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2023.1120533/full
- https://www.usada.org/spirit-of-sport/what-is-mots-c-peptide/
- https://www.federalregister.gov/documents/2026/10/30/2026-22192/compounding-enforcement-discretion-503a
Research This Peptide Further
Buy in shop
MOTS-c
5 verified vendors, side by side on real prices.
Frequently Asked Questions
What does MOTS-c do?
MOTS-c is a 16-amino-acid peptide your own mitochondria make, encoded inside the 12S rRNA region of mitochondrial DNA and discovered in 2015. It is studied as a metabolic regulator and a so-called exercise mimetic, because its levels rise when you work out and it improves insulin sensitivity in animals. The catch: the impressive results are almost entirely in mice, with no completed published human efficacy trials.
How does MOTS-c work?
MOTS-c works largely through the AMPK pathway, the cell's main energy and fuel-gauge system. The proposed route is that MOTS-c interferes with the folate-AICAR-one-carbon metabolism cycle, which raises AICAR and activates AMPK in skeletal muscle, liver, and fat. Once AMPK is switched on, cells burn more fatty acids, take up more glucose, and ramp up mitochondrial biogenesis. MOTS-c can also move into the cell nucleus under metabolic stress and influence stress-response genes, which is unusual for a mitochondrial peptide and is part of why it is framed as a stress-adaptive signal. Treat the exact pathway details as a working model rather than settled fact, since much of it is still being mapped.
Is MOTS-c FDA approved?
No, MOTS-c is not currently FDA approved. Current status: Preclinical/Early Clinical - FDA removed MOTS-c from Category 2 effective April 22, 2026. PCAC voted 7-5 to recommend MOTS-c for the 503A authorized compounding bulks list on July 23, 2026. The first Western Phase 2a RCT (NCT07505745, 120 participants with prediabetes, 16 weeks, primary endpoint: insulin sensitivity) is actively recruiting as of 2026. Non-binding advisory recommendation; formal FDA rulemaking required before legal compounding. No FDA approval for any indication. Effective October 30, 2026, HHS published Federal Register Document 2026-22192, an interim enforcement discretion policy that conditionally permits 503A compounding pharmacies to compound MOTS-c while formal rulemaking proceeds. Conditions include pharmaceutical-grade API sourcing, certificates of analysis, patient-specific prescriptions only, and single-API formulations only. This does not add MOTS-c to the FDA 503A Bulks Drug Substances List and is not a final rule. Rulemaking is pending with no timeline stated.
Is MOTS-c banned in sport?
Prohibited at all times under WADA S4 (metabolic modulators, AMPK activators), where MOTS-c is named.
What are the side effects of MOTS-c?
Reported side effects include: Generally well-tolerated, Injection site reactions (persistent bumps), Palpitations, Nausea and bloating, Fatigue. Individual responses vary based on dosage, duration, and personal health factors.
What is the typical dose of MOTS-c?
Community-reported common dose: 5-10 mg weekly (1-3x weekly). Range: 5-15 mg per week. Administration: Subcutaneous injection. Community-reported doses. Not medical advice. Consult healthcare provider.
Related Peptides
Peptides commonly compared with MOTS-c or used in similar applications.
Oxytocin
FDAOxytocin is a 9-amino-acid hormone made in the hypothalamus, famous as the chemistry behind labor contractions, breastfeeding, and social bonding. As an injectable drug it is FDA-approved to induce labor and control postpartum bleeding, but the intranasal 'love hormone' versions sold for trust, anxiety, and autism are experimental and the human results are genuinely mixed. The hype runs well ahead of the evidence.
HormonalRusfertide
FDARusfertide (brand name Mimrylo) is an injectable peptide that mimics hepcidin, the body's master hormone for controlling iron, and it is used to manage polycythemia vera (PV), a blood cancer that makes too many red blood cells. By limiting iron availability, it throttles red blood cell production and reduces the need for repeated blood draws (phlebotomy). It is not a research-only or gray-market peptide: the FDA approved it on August 28, 2026 for adults with PV, after a positive phase 3 trial.
HormonalCetrorelix
FDACetrorelix is a GnRH antagonist: a modified 10-amino-acid version of the brain's gonadotropin-releasing hormone that blocks its receptor instead of activating it. Sold as Cetrotide and FDA-approved since August 2000, its job in IVF is narrow and important: it stops the body's own LH surge from releasing eggs too early while the ovaries are being stimulated. It is a well-established fertility drug with decades of use, and it is not a tool for anything else people sometimes imagine it for.
HormonalHCG (Human Chorionic Gonadotropin)
FDAHCG is a hormone produced in pregnancy that happens to be an almost perfect mimic of luteinizing hormone. That single fact is why it has two completely unrelated uses: it is an approved fertility medicine, and it is the standard tool for keeping the testicles working during testosterone therapy. It is also the basis of the discredited HCG diet, which is a separate story and not supported by evidence.
HormonalKisspeptin
Clinical TrialsKisspeptin is the master switch that tells your brain to start reproduction. It is a family of peptides (the full length is kisspeptin-54, with shorter active fragments KP-14, KP-13, and KP-10) made from the KISS1 gene, and it acts as the upstream trigger for the entire reproductive hormone cascade. It is not an approved drug, but it has been tested in real human trials for fertility, hypothalamic amenorrhea, and male hypogonadism, with promising early results.
HormonalGonadorelin
Clinical TrialsGonadorelin is a synthetic copy of natural GnRH (gonadotropin-releasing hormone), a 10-amino-acid peptide (pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2) that tells the pituitary to release LH and FSH. It was once FDA-approved (Factrel) for testing pituitary function, but that brand is discontinued and no approved gonadorelin product is marketed in the US today. In the peptide world it is mostly used off-label to keep the testes working during testosterone replacement, and the catch is that timing matters enormously: pulse it and you stimulate, give it continuously and you shut the system down.
HormonalWant updates on MOTS-c research?
Get an email when we add new research here, when it is back in stock, or when the price drops.